LEO Pharma Open Innovation

PBMC inflammation assay

This assay is under development and will be available soon. The stimuli and detected response may be altered, however as an idea of the protocol: human peripheral blood mononuclear cells (PBMCs) will be presented with beads coated in CD3 & CD28, and exposed to IL-23 in the medium, to induce an inflammatory response, detected as an increase in IL-17 secretion. Your compound will be tested for its ability to inhibit this inflammatory response, measured as an inhibition of IL-17 release. Cellular viability will also be assessed, as a measure of general compound cytotoxicity.